|

POLA-R-CHP Clinical Trials

2 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1

Top Sponsors

  • The First Affiliated Hospital of Soochow University1
  • Fudan University1

Indications

  • Cancer2
  • DLBCL1
  • Diffuse Large B-cell Lymphoma(DLBCL)1
  • Diffuse Large B-Cell Lymphoma1

Other2 trials

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Phase 2
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.